CHANGES IN MBS BULK BILLING INCENTIVES ADDRESS GP CAPACITY IN WOMEN’S HEALTH Reforms expand professional pathways and clinical scope to meet the demands of patients
With
Dr Sneha Wadhwani, GP
Bondi Junction Medical & Dental Centre &
Conjoint Lecturer, UNSW Medical School &
Clinical Director NSW & ACT,
Head of GP Wellbeing & Women’s Health,
ForHealth Group &
Co-Founder & National Clinical Director
Evoca Women’s Health
SEGMENT
Filmed in Sydney | November 2025
Dr. Sneha Wadhwani, a General Practitioner in Bondi, and Conjoint Lecturer at UNSW School of Medicine, is actively involved in enhancing women’s health services across Australia. As the Co-founder and Clinical Director of Evoca Women’s Health, she highlights the significant improvements in funding for women’s health, particularly with the new MBS bulk billing incentives, in new codes, that commenced on November 1, 2025.
These codes facilitate bulk billing for essential services such as menopause health assessments and long-acting reversible contraceptives, enabling more women to access critical care at little or no cost. These advancements address long-standing challenges faced by GPs, including time constraints and inadequate funding, which have historically limited comprehensive women’s health care delivery.
The investment in training for IUDs and contraceptive implants is another vital component of this initiative, equipping more GPs to provide these services effectively. Dr. Wadhwani notes that the Evoca model prioritises GP-led, holistic care, with trained practitioners working alongside allied health professionals to support women through various stages of their lives.
With the expansion of Evoca clinics from one to 43 nationally and an expectation that 75% will eventually adopt bulk billing, Dr Wadhwani believes there is a significant opportunity for GPs interested in women’s health to upskill and serve women who have previously delayed care due to costs. Dr. Wadhwani emphasises that addressing women’s health has far-reaching effects on families and communities, creating a compelling call to action for clinicians to embrace these new incentives.
Source: Adapted from transcript
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
-
Brain cancer Professor mentors Tasmanian researchers
Rosemary Harrup trained in Victoria and Tasmania in Medical Oncology and Clinical Haematology, completing a dual Fellowship in 2001. She is the current Director of Cancer and Blood Services at the Royal Hobart Hospital (RHH), a role she has held since 2009.
Australian Health Journal spoke to Rosemary about her journey in medicine and specifically her work in Clinical Trials in Brain Cancer and the value she placed on her senior clinicians as mentors and how she now mentors others.
-
Lasers in dental treatment without needles and drills
In 2017, Dr. Omar Zuaiter and Alaa Habeb launched Dentroid, a dental technology startup with a mission to make dentistry a kinder and friendlier experience for patients and dentists using photonics (using laser technology) and robotics, as alternatives to needles, drills and sprays. The vision for the startup is to have dentistry adopt laser technology, addressing the root causes of dental pain & anxiety, and create a pain-free dental experience.
